Krystal Biotech (KRYS) Equity Ratio (2016 - 2026)

Krystal Biotech has disclosed Equity Ratio across 11 years of filings, most recently posting 0.91 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.91, changed 0.28% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.91 (changed 0.28% YoY), and the FY2025 annual result was 0.91, up 2.01% from the prior year.
• Equity Ratio came in at 0.91 for Q1 2026 at Krystal Biotech, roughly flat from 0.91 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.96 in Q3 2023 to a low of 0.89 in Q1 2022.
• The 5-year median for Equity Ratio is 0.92 (2025), against an average of 0.92.
• Peak annual rise in Equity Ratio reached 3.67% in 2022, while the deepest fall reached 8.52% in 2022.
• Krystal Biotech's Equity Ratio stood at 0.94 in 2022, then increased by 1.75% to 0.95 in 2023, then fell by 5.8% to 0.9 in 2024, then increased by 2.01% to 0.91 in 2025, then retreated by 0.05% to 0.91 in 2026.
• The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.91 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.